Literature DB >> 26423430

Delivery of epilepsy care to adults with intellectual and developmental disabilities.

Orrin Devinsky1, Miya Asato2, Peter Camfield2, Eric Geller2, Andres M Kanner2, Seth Keller2, Michael Kerr2, Eric H Kossoff2, Heather Lau2, Sanjeev Kothare2, Baldev K Singh2, Elaine Wirrell2.   

Abstract

Epilepsy is common in people with intellectual and developmental disabilities (IDD). In adulthood, patients with IDD and epilepsy (IDD-E) have neurologic, psychiatric, medical, and social challenges compounded by fragmented and limited care. With increasing neurologic disability, there is a higher frequency of epilepsy, especially symptomatic generalized and treatment-resistant epilepsies. The causes of IDD-E are increasingly recognized to be genetic based on chromosomal microarray analysis to identify copy number variants, gene panels (epilepsy, autism spectrum disorder, intellectual disability), and whole-exome sequencing. A specific genetic diagnosis may guide care by pointing to comorbid disorders and best therapy. Therapy to control seizures should be individualized, with drug selection based on seizure types, epilepsy syndrome, concomitant medications, and comorbid disorders. There are limited comparative antiepileptic drug data in the IDD-E population. Vagus nerve and responsive neural stimulation therapies and resective surgery should be considered. Among the many comorbid disorders that affect patients with IDD-E, psychiatric and sleep disorders are common but often unrecognized and typically not treated. Transition from holistic and coordinated pediatric to adult care is often a vulnerable period. Communication among adult health care providers is complex but essential to ensure best care when these patients are seen in outpatient, emergency room, and inpatient settings. We propose specific recommendations for minimum care standards for people with IDD-E.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26423430      PMCID: PMC4631073          DOI: 10.1212/WNL.0000000000002060

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

Review 1.  Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research.

Authors:  R Hochstenbach; J E Buizer-Voskamp; J A S Vorstman; R A Ophoff
Journal:  Cytogenet Genome Res       Date:  2011-11-02       Impact factor: 1.636

2.  Risk factors for injuries and falls among adults with developmental disabilities.

Authors:  K Hsieh; T Heller; A B Miller
Journal:  J Intellect Disabil Res       Date:  2001-02

Review 3.  A decade of the modified Atkins diet (2003–2013): Results, insights, and future directions.

Authors:  Eric H Kossoff; Mackenzie C Cervenka; Bobbie J Henry; Courtney A Haney; Zahava Turner
Journal:  Epilepsy Behav       Date:  2013-12       Impact factor: 2.937

4.  Long-term mortality in childhood-onset epilepsy.

Authors:  Matti Sillanpää; Shlomo Shinnar
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

5.  Seizure-related injuries in multihandicapped patients with therapy-resistant epilepsy.

Authors:  K O Nakken; R Lossius
Journal:  Epilepsia       Date:  1993 Sep-Oct       Impact factor: 5.864

6.  Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features.

Authors:  Agatino Battaglia; Viola Doccini; Laura Bernardini; Antonio Novelli; Sara Loddo; Anna Capalbo; Tiziana Filippi; John C Carey
Journal:  Eur J Paediatr Neurol       Date:  2013-05-24       Impact factor: 3.140

Review 7.  What do you do when they grow up? Approaches to seizures in developmentally delayed adults.

Authors:  Orrin Devinsky
Journal:  Epilepsia       Date:  2002       Impact factor: 5.864

8.  Outcome of childhood epilepsy: a population-based study with a simple predictive scoring system for those treated with medication.

Authors:  C Camfield; P Camfield; K Gordon; B Smith; J Dooley
Journal:  J Pediatr       Date:  1993-06       Impact factor: 4.406

9.  A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life.

Authors:  Michael P Kerr; Gus A Baker; Martin J Brodie
Journal:  Epilepsy Behav       Date:  2005-09-02       Impact factor: 2.937

10.  Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial.

Authors:  Christianne N Heck; David King-Stephens; Andrew D Massey; Dileep R Nair; Barbara C Jobst; Gregory L Barkley; Vicenta Salanova; Andrew J Cole; Michael C Smith; Ryder P Gwinn; Christopher Skidmore; Paul C Van Ness; Gregory K Bergey; Yong D Park; Ian Miller; Eric Geller; Paul A Rutecki; Richard Zimmerman; David C Spencer; Alica Goldman; Jonathan C Edwards; James W Leiphart; Robert E Wharen; James Fessler; Nathan B Fountain; Gregory A Worrell; Robert E Gross; Stephan Eisenschenk; Robert B Duckrow; Lawrence J Hirsch; Carl Bazil; Cormac A O'Donovan; Felice T Sun; Tracy A Courtney; Cairn G Seale; Martha J Morrell
Journal:  Epilepsia       Date:  2014-02-22       Impact factor: 5.864

View more
  5 in total

1.  Under representation of people with epilepsy and intellectual disability in research.

Authors:  Rohit Shankar; Charles Rowe; Alje Van Hoorn; William Henley; Richard Laugharne; David Cox; Raj Pande; Ashok Roy; Josemir W Sander
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

2.  Prevalence and incidence of physical health conditions in people with intellectual disability - a systematic review.

Authors:  Peiwen Liao; Claire Vajdic; Julian Trollor; Simone Reppermund
Journal:  PLoS One       Date:  2021-08-24       Impact factor: 3.240

3.  Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice.

Authors:  Gregory S Connor; Amanda Williamson
Journal:  Epilepsy Behav Rep       Date:  2022-03-10

4.  The Genetic Diagnosis of Ultrarare DEEs: An Ongoing Challenge.

Authors:  Luciana Musante; Paola Costa; Caterina Zanus; Flavio Faletra; Flora M Murru; Anna M Bianco; Martina La Bianca; Giulia Ragusa; Emmanouil Athanasakis; Adamo P d'Adamo; Marco Carrozzi; Paolo Gasparini
Journal:  Genes (Basel)       Date:  2022-03-12       Impact factor: 4.096

5.  An emerging spectrum of variants and clinical features in KCNMA1-linked channelopathy.

Authors:  Jacob P Miller; Hans J Moldenhauer; Sotirios Keros; Andrea L Meredith
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.